ARAY
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Accuray Incorporated is a radiation therapy company that develops, manufactures, sells, and supports treatment delivery, planning, imaging, and data management solutions for clinical teams. The company's portfolio includes the CyberKnife robotic platform and a helical portfolio comprising the Accuray Stellar, Radixact, Accuray Helix, and Tomo C Systems. These systems support advanced radiation treatments such as stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy (IGRT). Accuray provides software-enabled motion management, treatment planning, and ClearRT helical kVCT imaging technology to support adaptive workflows and personalized treatment delivery. The company serves radiation oncologists and neurosurgeons treating patients with cancerous or benign tumors, as well as selected neurologic and endocrine disorders. Accuray operates in the United States and international markets, including Europe, Asia, and Latin America, through regional offices and distributors. The company was incorporated in 1990 and commenced operations in 1992. It maintains strategic partnerships, including an agreement with RaySearch Laboratories AB for treatment planning integration.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Medical Devices Homepage accuray.com
Sector Healthcare IR page accuray.com
Tags
radiation therapy, stereotactic radiosurgery, robotic surgery, image-guided radiation therapy, treatment planning software, motion management, adaptive radiotherapy, oncology, CyberKnife, Accuray Stellar, Radixact, Accuray Helix, Tomo C Systems, ClearRT, RayStation Treatment Planning System
Press page —

Metrics

Valuation  
Market cap $ 32.297M
Market cap (USD) $ 32.297M
P/E -1.80
PEG —
P/BV 0.61
P/S 0.08
P/OCF -4.63
P/FCF -2.51
Dividend yield —
Turnover / mcap —
Returns  
ROE -80.1%
ROI -26.0%
ROIC -10.5%
Profit margin -12.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 191.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 401.947M 458.505M 446.551M 447.605M 429.909M 396.289M 382.928M 418.785M 404.897M 383.414M 398.8M 379.801M 369.419M 315.974M 409.223M 222.284M 233.598M 210.381M 140.452M 52.897M
Net profit -49.194M -1.591M -15.545M -9.28M -5.347M -6.311M 3.827M -16.43M -23.899M -29.579M -25.504M -40.209M -35.448M -116.508M -78.453M -27.111M 609K 5.383M -5.616M -33.694M
Free cash flow -12.842M -1.412M -15.505M 2.925M -7.117M 36.192M -5.027M -33.952M 12.055M -5.411M 25.472M -27.178M -11.585M -81.303M -49.048M 8.381M -12.278M -23.019M 4.367M 11.903M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006
Share price 0.26 1.37 1.82 3.87 1.96 4.52 2.03 3.87 4.1 4.75 5.19 6.74 8.8 5.74 6.82 8 6.67 8.75 18 —
Price performance 12m -0.81 -0.25 -0.53 0.97 -0.57 1.23 -0.48 -0.06 -0.14 -0.08 -0.23 -0.23 0.53 -0.16 -0.15 0.22 -0.24 -0.51 — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 72.8M 66M 112M 90.6M 85.4M 94.4M 74.8M 92M 83.2M 67.4M
↳ YoY growth +2,680.3% -9.3% +69.5% -19.0% -5.8% +10.6% -20.8% +23.0% -9.6% -19.0%
↳ 5y CAGR +144.7% +100.8% +5.3% +2.5% -3.8% -1.7% -4.6%
Borrowings, current (USD) 113M — — — 7.58M 17.1M 11.4M 15.5M 12.7M 1.5M
Borrowings, non-current (USD) 51.5M 131M 160M 189M 170M 172M 172M 164M 124M 146M
Lease liabilities (USD) — — 34.5M 32.4M 25.6M 19M 27.8M 38.6M 39.9M 36M
Cash and deposits (USD) 72.1M 83.1M 76.8M 108M 116M 88.7M 89.4M 68.6M 57.4M 40.6M
Intangible assets (USD) 964,000 821,000 679,000 663,000 435,000 250,000 210,000 59,000 15,000 0.00
Right-of-use assets (USD) — — 30.6M 28.6M 22.5M 16.8M 25.9M 33.8M 33.1M 27.5M
Net debt (borrowings + leases - cash) (USD) 92.5M 48M 83M 114M 86.8M 119M 121M 150M 119M 143M
Cash flow detail
Operating cash flow (USD) -380,000 18.3M -29.6M -1.47M 38.5M -2.4M 15.5M -11.9M 2.86M -6.98M
Purchases of property, plant and equipment (USD) -5.03M -6.28M -4.31M -3.56M -2.32M -4.72M -12.6M -3.6M -4.27M -5.86M
Purchases of intangible assets (USD) -333,000 -333,000 — -170,000 0.00 0.00 -67,000 0.00 — —
Change in receivables (cash effect) (USD) -15.7M 7.22M -46.2M 19M 5.24M -12.5M 18.5M -15.8M 13.4M 11.5M
Change in inventories (cash effect) (USD) 7.68M -8.69M -14.2M -23.2M 1.69M -22.9M -6.86M -4M -9.11M -12.5M
Change in payables (cash effect) (USD) 2.19M 2M 9.46M -6.77M -3.98M 11.7M 2.85M 17.4M -18.7M 5.17M
Share buybacks (cash effect) (USD) — — — 0.00 -14.1M 0.00 0.00 — — —
Interest paid (cash effect) (USD) -9.93M -9.19M -9.76M -12.3M -11.9M -7.46M -9.85M -10.5M -9.74M -13.9M
Income taxes paid (cash effect) (USD) -4.46M -1.46M -2.19M -2.81M -1.87M -1.4M -2.15M -1.75M -3.87M -2.32M
Share-based compensation (USD) 13.6M 12.3M 10.6M 8.15M 9.33M 10.6M 10.1M 9.48M 10.2M 6.46M
Operating cash flow before change in receivables (USD) 15.4M 11.1M 16.5M -20.5M 33.3M 10.1M -2.95M 3.92M -10.5M -18.5M
Free cash flow (OCF - PPE - intangibles) (USD) -5.74M 11.7M -34M -5.2M 36.2M -7.12M 2.86M -15.5M -1.41M -12.8M
Income detail
Research and development expense (USD) 49.9M 57.3M 56.5M 49.8M 52.7M 57.8M 57.1M 49.7M 47.9M 37.8M
↳ 5y CAGR -10.5% -2.9% +1.0% -2.2% -1.4% +3.0% 0.0% -2.5% -0.8% -6.5%
Total comprehensive income (USD) -28.7M -22.8M -17.5M 3.35M -3.73M -5.03M -11.3M -20.2M 794,000 -50.9M
Comprehensive income to owners (USD) -28.7M -22.8M -17.5M 3.35M -3.73M -5.03M -11.3M -20.2M 794,000 -50.9M
Provision for credit losses (USD) 119,000 — 3.68M 1.8M 133,000 266,000 2.29M -479,000 -101,000 —
Credit cost ratio (credit losses / average receivables) (%) 0.3% — 4.1% 1.8% 0.2% 0.3% 2.7% 0.6% 0.1% —
Reported Aug 25, 2017 Aug 24, 2018 Aug 17, 2021 Aug 17, 2022 Aug 17, 2022 Aug 17, 2022 Sep 7, 2023 Sep 19, 2024 Aug 28, 2025 Aug 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MADISON, Wis., Nov. 13, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it has completed its financing transaction with TCW Asset Management Company LLC ("TCW"), the company's primary lender and largest shareholder. The transaction significantly reduces Accuray's debt, adds new capital and waives certain financial covenants through December 31, 2027. Together, these steps put the company's balance sheet on a firmer footing as it carries out the next phase of its previously announced strategic transformation.

The closing follows stockholder approval of all transaction-related proposals at Accuray's Special Meeting of Stockholders on October 6, 2026, and the 1-for-40 reverse stock split of the company's common stock, which took effect on November 9, 2026.

With the closing, the following terms are now in effect among other components:

• Deleveraging: TCW has exchanged $40 million in aggregate principal amount of its term loan for convertible preferred stock.

• Equity investment: TCW invested $15 million in cash when the transaction agreements were signed in July.

November 4, 2026 at 4:05 PM EST

MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2026.

Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

Key Highlights

  • Service revenue grew 4% year-over-year to $59.2 million, up 5% on a constant currency basis, driven by service contract pricing actions and nearly 3% growth in the global installed base.

  • Service gross margin rose 120 basis points from the prior year to 35.1%, primarily driven by pricing actions and a lower service labor cost structure.

  • Operating expenses were $62.6 million in the first quarter of fiscal 2027, including a $35.4 million non-cash goodwill impairment charge. Excluding the goodwill impairment charge, operating expenses fell 29% to $27.2 million from $38.3 million in the prior year first quarter, as transformation initiatives continued to deliver measurable results. Overall, transformation initiatives generated approximately $13 million of cost and margin improvement year over year; driven by headcount reductions, more efficient usage of strategic partners, focused product development and marketing plans, and continued discretionary spending discipline.

  • Accuray signed a definitive agreement with RaySearch to accelerate its online adaptive radiation therapy strategy. It also advanced its collaboration with Samsung NeuroLogica on volumetric imaging for the CyberKnife System.

  • Long-term PACE-A data presented at ASTRO showed excellent eight-year biochemical control for SBRT, with about 75% of SBRT patients treated with the CyberKnife System. SBRT also showed quality-of-life advantages over surgery.

  • The Company's financial foundation was strengthened by the $15 million investment associated with its previously announced financing transaction with TCW in July. After quarter end, stockholders approved the proposals needed to help enable the Company to complete the financing transaction with TCW, including the $40 million exchange of term loan debt for convertible preferred equity. These actions are intended to reduce leverage, enhance liquidity, and provide greater flexibility to execute our strategy.

"As I said on our last call, fiscal 2026 was a year of transformation, and fiscal 2027 is about execution," said Steve La Neve, President and Chief Executive Officer of Accuray. "During the first quarter, we made progress across several areas. Service margins improved, operating expenses remained well controlled, we strengthened our financial position, and we advanced our innovation roadmap through strategic partnerships with RaySearch and Samsung NeuroLogica. By combining our strengths in precision treatment delivery and real-time motion management with enhanced imaging and adaptive capabilities, we believe we can further differentiate our platforms and deliver greater value for clinicians and patients."

Mr. La Neve continued, "At the same time, we see a clear opportunity to improve product and order performance. The customer engagement we saw at ASTRO, the growing clinical evidence supporting precision radiation therapy, and the opportunities created by our innovation strategy reinforce our confidence in the direction we are taking. Our focus now is on turning that engagement into orders and revenue, and on pairing the operating discipline we have built with stronger commercial performance. We know what we need to execute, and our team is focused on delivering."

Fiscal****First Quarter Results

Total net revenue was $86.5 million in the first quarter of fiscal 2027, or a decrease of 8 percent, as compared to $93.9 million in the prior fiscal year first quarter. Product revenue was $27.3 million in the first quarter of fiscal 2027, or a decrease of 26 percent, as compared to $37.2 million in the prior fiscal year first quarter. Service revenue was $59.2 million in the first quarter of fiscal 2027, or an increase of 4 percent, as compared to $56.8 million in the prior fiscal year first quarter.

Total gross profit was $26.1 million in the first quarter of fiscal 2027, or 30.1 percent of total net revenue, as compared to a total gross profit of $27.0 million, or 28.8 percent of total net revenue, in the prior fiscal year first quarter. The increase in gross margin rate was primarily due to a higher service gross margin rate, reflecting ongoing pricing initiatives.

Operating expenses were $62.6 million in the first quarter of fiscal 2027, including a $35.4 million non-cash goodwill impairment charge. Excluding the goodwill impairment charge, operating expenses were $27.2 million, a decrease of 29 percent compared to the prior fiscal year first quarter. Operating expenses in the first quarter of fiscal 2027 included $0.4 million in restructuring charges, as compared to $2.8 million in the prior year. Excluding goodwill impairment, operating expenses decreased across all operating expense categories as a result of the Company's disciplined execution of its transformation initiatives.

The Company recognized a gain on extinguishment of debt of approximately $59.6 million in connection with its July 2026 financing transaction. The transaction added a substantive contingent conversion feature to the outstanding Term Loan B and Delayed Draw Term Loan, resulting in extinguishment accounting and initial recognition of the replacement loans at fair value. The gain primarily reflected the difference between the net carrying amounts of the existing loans and the fair value of the replacement loans. Recognition of the gain did not depend on completion of the debt-for-equity exchange, which remained subject to closing conditions at September 30, 2026, including requisite stockholder approval and implementation of a reverse stock split.

Net income was $10.1 million in the first quarter of fiscal 2027, or a diluted net income of $0.07 per share, including the $59.6 million non-cash gain on extinguishment of debt and $35.4 million non-cash goodwill impairment charge. Excluding both items, net loss was $14.0 million in the first quarter of fiscal 2027, or a diluted net loss of $0.10 per share, as compared to a net loss of $21.7 million, or a diluted net loss of $0.18 per share, in the prior fiscal year first quarter. Adjusted EBITDA was $2.5 million in the first quarter of fiscal 2027, as compared to a negative adjusted EBITDA of $4.1 million in the prior fiscal year first quarter.

Gross product orders were $19.8 million in the first quarter of fiscal 2027 as compared to $39.6 million in the prior fiscal year first quarter. The book to bill ratio was 0.7 in the first quarter of fiscal 2027, as compared to 1.1 the prior fiscal year first quarter. Order backlog as of September 30, 2026 was $272.0 million, which is approximately 31% percent lower than at the end of the prior fiscal year first quarter.

Total cash, cash equivalents and restricted cash as of quarter end amounted to $50.4 million, an increase of $1.6 million from June 30, 2026.

Fiscal Year 2027 Financial Guidance

The Company continues not to provide formal revenue or Adjusted EBITDA guidance for fiscal 2027. After a fiscal 2026 focused on transformation, its priority in fiscal 2027 is execution. That means building on the progress made in service margins, cost structure and financial flexibility, and turning commercial engagement into stronger product revenue and order performance. With a more efficient business model in place, the Company believes it is well positioned to execute on its strategic priorities in fiscal 2027.

Conference Call Information

Accuray will host a conference call beginning at 3:30 p.m. CT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2027 as well as recent corporate developments. Conference call dial-in information is as follows:

  • U.S. callers: (800) 715-9871

  • International callers: (646) 307-1963

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (855) 669-9658 (USA), or (412) 317-0088 (International), Conference ID: 7745341. An archived webcast will also be available on Accuray's website until Accuray announces its results for the second quarter of fiscal 2027.

Use of Non-GAAP Financial Measures

Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA and revenue on a constant currency basis.

Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, changes to the fair value of warrant liability, gain on extinguishment of debt, goodwill impairment and restructuring charges ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements that are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations and financial position, including expectations regarding: the company's service margins, backlog, age-ins and age-outs, cancellations of contracts and foreign currency impacts; the expected impact of changes to strengthen the company's commercial organization and improve execution; expectations regarding the effects of the global macroeconomic conditions on the company's financial results and business; the company's ability to further differentiate its platforms and deliver greater value; the company's ability to execute on delivering stronger commercial performance; the company's ability to execute on its strategic priorities in fiscal 2027; expectations related to the company's credit facilities; the expected benefits from the transformation plan and refinancing transactions; the ability to achieve the objectives of the transformation plan; the company's ability to deliver sustained performance and execute on its strategies and objectives, including related to its transformation efforts; the company's ability to improve sales and drive margin expansion; opportunities to accelerate top-line growth and expand profitability; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding installed base growth; and the company's ability to improve execution, drive sustainable, profitable growth, while creating long-term value for patients, providers and shareholders. Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "may," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; effects related to international tariffs; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the company's ability to successfully implement its transformation plan; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; geopolitical uncertainty, including armed conflict or political instability in the Middle East or other regions in which the company or its customers operate, and the effect of such conditions on the timing of system installations, customer site readiness, service revenue recognition, and the ability to complete transactions in affected markets; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 27, 2026, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

| Aman Patel, CFA | Steve Monroe |

| Investor Relations, ICR - Westwicke | Vice President, Financial Planning & Analysis - Accuray |

| [email protected] | [email protected] |

Financial Tables to Follow

| Accuray Incorporated Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited) |

| |

| | | Three Months Ended | |

| | | September 30, | |

| | | 2026 | | | 2025 | |

| Net revenue: | | | | | | | | |

| Products | | $ | 27,344 | | | $ | 37,161 | |

| Services | | | 59,179 | | | | 56,781 | |

| Total net revenue | | | 86,523 | | | | 93,942 | |

| Cost of revenue: | | | | | | | | |

| Cost of products | | | 22,047 | | | | 29,422 | |

| Cost of services | | | 38,392 | | | | 37,509 | |

| Total cost of revenue | | | 60,439 | | | | 66,931 | |

| Gross profit | | | 26,084 | | | | 27,011 | |

| Operating expenses: | | | | | | | | |

| Research and development | | | 7,811 | | | | 11,218 | |

| Selling and marketing | | | 8,681 | | | | 11,699 | |

| General and administrative | | | 10,319 | | | | 12,596 | |

| Restructuring | | | 383 | | | | 2,811 | |

| Goodwill impairment | | | 35,392 | | | | — | |

| Total operating expenses | | | 62,586 | | | | 38,324 | |

| Loss from operations | | | (36,502) | | | | (11,313) | |

| Income from equity method investment, net | | | 114 | | | | 439 | |

| Interest expense | | | (11,828) | | | | (8,052) | |

| Gain on extinguishment of debt | | | 59,563 | | | | — | |

| IEEPA refund financing costs | | | (55) | | | | — | |

| Loss from change in fair value of warrant liability | | | (707) | | | | (1,874) | |

| Other income (expense), net | | | 66 | | | | (407) | |

| Income (loss) before provision for income taxes | | | 10,651 | | | | (21,207) | |

| Provision for income taxes | | | 517 | | | | 471 | |

| Net income (loss) | | $ | 10,134 | | | $ | (21,678) | |

| Net income (loss) per share - basic | | $ | 0.07 | | | $ | (0.18) | |

| Net income (loss) per share - diluted | | $ | 0.07 | | | $ | (0.18) | |

| Weighted average common shares used in computing net income (loss) per share: | | | | | | | | |

| Basic | | | 138,202 | | | | 118,946 | |

| Diluted | | | 139,256 | | | | 118,946 | |

| Accuray Incorporated Condensed Consolidated Balance Sheets (in thousands) (Unaudited) |

| |

| | | September 30, 2026 | | | June 30, 2026 | |

| Assets | | | | | | | | |

| Current assets: | | | | | | | | |

| Cash and cash equivalents | | | 42,254 | | | $ | 40,623 | |

| Restricted cash | | | 827 | | | | 611 | |

| Accounts receivable, net | | | 50,343 | | | | 67,409 | |

| Inventories, net | | | 146,083 | | | | 147,075 | |

| Prepaid expenses and other current assets | | | 26,342 | | | | 31,783 | |

| Deferred cost of revenue | | | 199 | | | | 276 | |

| Total current assets | | | 266,048 | | | | 287,777 | |

| Noncurrent assets: | | | | | | | | |

| Property and equipment, net | | | 25,916 | | | | 27,316 | |

| Investment in joint venture | | | 5,311 | | | | 5,024 | |

| Operating lease right-of-use assets, net | | | 26,131 | | | | 27,512 | |

| Goodwill | | | 22,524 | | | | 57,911 | |

| Long-term restricted cash | | | 7,302 | | | | 7,533 | |

| Other assets | | | 36,823 | | | | 30,603 | |

| Total assets | | $ | 390,055 | | | $ | 443,676 | |

| Liabilities and stockholders' equity | | | | | | | | |

| Current liabilities: | | | | | | | | |

| Accounts payable | | $ | 33,050 | | | $ | 40,554 | |

| Accrued compensation | | | 12,732 | | | | 15,666 | |

| Operating lease liabilities, current | | | 7,849 | | | | 8,236 | |

| Other accrued liabilities | | | 23,244 | | | | 32,235 | |

| Customer advances | | | 9,578 | | | | 10,401 | |

| Deferred revenue, current | | | 76,953 | | | | 82,813 | |

| Short-term debt, net | | | 6,700 | | | | 1,500 | |

| Total current liabilities | | | 170,106 | | | | 191,405 | |

| Non current liabilities: | | | | | | | | |

| Operating lease liabilities, non-current | | | 26,453 | | | | 27,768 | |

| Long-term other liabilities | | | 6,107 | | | | 5,477 | |

| Warrant liability | | | 6,489 | | | | 2,427 | |

| Deferred revenue, non-current | | | 24,836 | | | | 28,530 | |

| Investor deposit obligation | | | 7,975 | | | | — | |

| Long-term debt, net | | | 94,972 | | | | 146,370 | |

| Total liabilities | | | 336,938 | | | | 401,977 | |

| Stockholders' equity: | | | | | | | | |

| Common stock | | | 120 | | | | 119 | |

| Additional paid-in capital | | | 612,552 | | | | 613,559 | |

| Accumulated other comprehensive loss | | | (1,223) | | | | (3,513) | |

| Accumulated deficit | | | (558,332) | | | | (568,466) | |

| Total stockholders' equity | | | 53,117 | | | | 41,699 | |

| Total liabilities and stockholders' equity | | $ | 390,055 | | | $ | 443,676 | |

| Accuray Incorporated Summary of Orders and Backlog (in thousands, except book to bill ratio) (Unaudited) |

| |

| | | Three Months Ended | |

| | | September 30, | |

| | | 2026 | | | 2025 | |

| Gross orders | | $ | 19,846 | | | $ | 39,570 | |

| Net orders | | $ | (13,235) | | | $ | 5,915 | |

| Order backlog | | $ | 271,970 | | | $ | 395,726 | |

| Book to bill ratio (a) | | | 0.7 | | | | 1.1 | |

| | (a) | Book to bill ratio is defined as gross orders for the period divided by product revenue for the period. |

| Accuray Incorporated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands) (Unaudited) |

| |

| | | Three Months Ended | |

| | | September 30, | |

| | | 2026 | | | 2025 | |

| GAAP net income (loss) | | $ | 10,134 | | | $ | (21,678) | |

| Depreciation and amortization (a) | | | 2,027 | | | | 1,676 | |

| Stock-based compensation | | | 1,121 | | | | 2,515 | |

| Interest expense, net (b) | | | 11,697 | | | | 7,780 | |

| Gain on extinguishment of debt | | | (59,563) | | | | — | |

| Goodwill impairment | | | 35,392 | | | | — | |

| Provision for income taxes | | | 517 | | | | 471 | |

| Loss from change in fair value of warrant liability | | | 707 | | | | 1,874 | |

| IEEPA refund financing costs | | | 55 | | | | — | |

| Restructuring charges | | | 383 | | | | 2,811 | |

| Post-financing costs | | | — | | | | 441 | |

| Adjusted EBITDA | | $ | 2,470 | | | $ | (4,110) | |

| | (a) | Consists of depreciation on property and equipment and amortization of capitalized software and intangibles. |

| | (b) | Consists of interest expense net of interest income. |

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2027-first-quarter-financial-results-302929651.html

SOURCE Accuray Incorporated

Connect with us on social media.

Linkedin Facebook Twitter Youtube

Accuray Announces 1-for-40 Reverse Stock Split Bull 0 Bear 4 Routine

November 4, 2026 at 4:20 PM EST

MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- **Accuray Incorporated (NASDAQ: ARAY)**announced today that its Board of Directors has approved a 1-for-40 reverse stock split of the Company's common stock and a corresponding decrease to the authorized number of shares of common stock. The reverse stock split is intended to increase the per-share trading price of the Company's common stock and enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market ("Nasdaq").

Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

The reverse stock split will become effective at 12:02 a.m. Eastern Time on November 9, 2026. The Company's common stock is expected to begin trading on a split-adjusted basis when the Nasdaq market opens on November 9, 2026 under the Company's existing trading symbol, "ARAY," with a new CUSIP number of 004397 303.

At the effective time of the reverse stock split, every 40 shares of the Company's common stock issued and outstanding will automatically be combined into one share of common stock. This will reduce the number of shares of common stock issued and outstanding from approximately 120.2 million shares to approximately 3.0 million shares, subject to adjustment for fractional shares. In addition, the total number of authorized shares of the Company's common stock will be proportionately reduced in accordance with the 1-for-40 ratio, from 400,000,000 shares to 10,000,000 shares. The number of authorized shares of the Company's preferred stock will not be adjusted as a result of the reverse stock split. The reverse stock split will affect all stockholders uniformly and will not change any stockholder's percentage ownership interest in the Company, except to the extent resulting from the treatment of fractional shares.

No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will receive cash in lieu of a fractional share.

Proportionate adjustments will also be made, as applicable, to the number of shares underlying the Company's outstanding equity awards and other securities, as well as the applicable exercise or conversion prices and the number of shares available for issuance under the Company's equity incentive plans. The reverse stock split will not change the par value of the Company's common stock.

Computershare Trust Company, N.A. ("Computershare") is acting as the exchange agent for the reverse stock split. Stockholders holding shares electronically in book-entry form or through a broker, bank or other nominee generally will have their holdings automatically adjusted to reflect the reverse stock split, subject to the processes of their broker, bank or nominee. Stockholders holding shares of the Company's common stock in certificate form will receive a transmittal letter from Computershare with instructions after the effective date.

About Accuray Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements that are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to statements regarding the implementation of the reverse stock split, the anticipated timing of trading of Accuray's common stock on a split-adjusted basis, the effect of the reverse stock split on the trading price of Accuray's common stock, and Accuray's ability to regain and maintain compliance with Nasdaq's continued listing requirements. Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "may," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the effect of the global macroeconomic environment on the operations of the company; effects related to international tariffs; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; geopolitical uncertainty, including armed conflict or political instability in the Middle East or other regions in which the company or its customers operate, and the effect of such conditions on the timing of system installations, customer site readiness, service revenue recognition, and the ability to complete transactions in affected markets; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 27, 2026, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Investor Contact Steve Monroe VP, Financial Planning & Analysis, Accuray [email protected]

Media Contact Taylor Bould Communications Specialist, Accuray [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-1-for-40-reverse-stock-split-302929758.html

SOURCE Accuray Incorporated

Connect with us on social media.

Linkedin Facebook Twitter Youtube

Prompts

Accuray Incorporated (ticker ARAY), listed in United States.

Company History

Date Change Detail
May 10, 2011 Acquired Acquired TomoTherapy Inc (CIK 1317872). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Accuray Incorporated

ETF Weight in ETF Shares Market value As of
FESM 0.01% 1,188,711 $ 306.45K Jun 30, 2026
MSSM 0.00% 122,675 $ 32.264K Aug 31, 2026